Reporte zur Charge EFE3590

Symptomtext

Drug ineffective; covid-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 49-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 14Feb2021 as dose 1, single (Lot number: EN6201), in right arm, on 07May2021 as dose 2, single (Lot number: EN6208), in right arm and on 14Oct2021 as dose 3 (booster), single (Lot number: EFE3590) at the age of 48 years, in right arm for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: CRESTOR, start date: 08Apr2022, stop date: 12Jul2022. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "not recovered"; COVID-19 (medically significant), outcome "not recovered". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Treatment of COVID-19; (24Jul2022) Positive, notes: I used a Siemens's antigen test. It was positive on 24Jul (7 days after my last). Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical information: Patient received other medications in two weeks of vaccination. Treatment started on 12Jul2022. Treatment stopped on 17Jul2022. Six days after of last dose of Paxlovid, patient started experiencing cold like symptoms: congestion, some sneezing, sinus pressure. Initially thinking it could be seasonal allergies or potential for sinus infection. After reading so many journals and articles on "rebound" with Paxlovid, patient used a Siemens's antigen test. It was positive on 24Jul (7 days after her last dose). Known allergies and other medical history were reported as No.